Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) were up 5.5% during mid-day trading on Wednesday . The stock traded as high as $16.40 and last traded at $16.37, with a volume of 106,963 shares changing hands. The stock had previously closed at $15.51.

Several analysts have recently issued reports on RVNC shares. Guggenheim restated a “buy” rating and issued a $55.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Brean Capital reiterated a “buy” rating on shares of Revance Therapeutics in a research report on Saturday, June 4th. SunTrust Banks Inc. reduced their target price on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, June 14th. Zacks Investment Research upgraded Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $35.00 target price (down from $54.00) on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $39.60.

The company has a 50-day moving average price of $13.97 and a 200-day moving average price of $16.73. The stock’s market cap is $441.93 million.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.02. The firm earned $0.80 million during the quarter, compared to the consensus estimate of $0.06 million. The business’s revenue was up .0% compared to the same quarter last year. Analysts anticipate that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current year.

An institutional investor recently raised its position in Revance Therapeutics stock. Schwab Charles Investment Management Inc. boosted its stake in shares of Revance Therapeutics Inc. (NASDAQ:RVNC) by 35.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 63,467 shares of the biopharmaceutical company’s stock after buying an additional 16,625 shares during the period. Schwab Charles Investment Management Inc. owned 0.23% of Revance Therapeutics worth $2,169,000 at the end of the most recent quarter.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.